Patent application number | Description | Published |
20090042268 | IMINOSUGAR COMPOUNDS WITH ANTIFLAVIRUS ACTIVITY - An anti-viral compounds effective against viruses belonging to the Flaviviridae family, wherein the anti-viral compounds are 1,5-dideoxy-1,5-imino-D-glucitol derivative compounds having the general formula (I) | 02-12-2009 |
20090088397 | INHIBITORS OF SECRETION OF HEPATITIS B VIRUS ANTIGENS FOR TREATMENT OF A CHRONIC HEPATITIS VIRUS - A pharmaceutical composition comprising an effective amount of a compound of formulas (I-III) and a pharmaceutically acceptable carrier. Methods for treating a hepatitis virus in a patient comprising administering an effective amount of the compound of formulas (I-III) are also presented. | 04-02-2009 |
20090208926 | DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESSMENT OF PROTEIN GLYCOSYLATION - Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting glycosylation, and more specifically fucosylation, on proteins in biological fluids, and comparing the detected glycosylation with reference values for the glycosylation of such proteins in healthy or disease states. | 08-20-2009 |
20090253180 | DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESSMENT OF ANTI-GAL IgG GLYCOSYLATION - Methods for diagnosing pathology of the liver in subject suspected of having such pathology by measuring the glycosylation of anti-gal IgG in various biological fluids of the subject. | 10-08-2009 |
20100137365 | Long chain N-alkyl compounds and oxa-derivatives thereof - Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C | 06-03-2010 |
20100285469 | METHOD OF TUMOR SCREENING - A method for tumor screening using urine of a mammal, the method includes obtaining a total urine nucleic acid (e.g., DNA) from a urine sample of a mammal, extracting a high molecular weight urine nucleic acid (above 1000 bp) by contacting the total urine nucleic acid with an adsorbent in the presence of a buffer which promotes binding of the high molecular weight urine nucleic acid to the adsorbent, replacing the buffer which promotes binding of the high molecular weight urine nucleic acid with a buffer which promotes binding of the low molecular weight urine nucleic acid to the adsorbent, extracting the low molecular weight urine nucleic acid by contacting with the adsorbent, eluting the low molecular weight urine nucleic acid, and assaying the low molecular weight urine nucleic acid for a presence or absence of a gene sequence specific to a certain type of tumor. | 11-11-2010 |
20100317127 | DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESMENT OF PROTEIN GLYCOSYLATION - Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy or disease states. | 12-16-2010 |
20110184019 | Long chain N-Alkyl compounds and oxa-derivatives thereof - Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C | 07-28-2011 |
20110189771 | Novel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity and Reducted Toxicity - Imino sugars, such as deoxynojirimycin (DNJ), are glucose analogues that selectively inhibit cellular α-glucosidase I and II (enzymes that process N-linked glycans in glycoprotein) and exhibit broad spectrum antiviral activities against many enveloped viruses. Previously we have reported a novel DNJ derivative, OSL-95II, with antiviral activity and reduced cytotoxicity. In order to develop imino sugars with more potent antiviral activity as well as improved toxicity profile, OSL-95II was modified by diversifying the nitrogen linked alkylated side chain. The antiviral activities were initially tested in bovine viral diarrhea virus (BVDV) infected MDBK cells, yielding several imino sugar derivatives with novel structure and superior antiviral activity and toxicity profile. Furthermore, these new compounds were shown to be active against Dengue virus (DV) and West Nile virus (WNV) infection in BHK cells where potent anti-DV activity having submicromolar EC50 values and SI of greater than 900. These compounds represent a new generation of iminio sugars and their analogues, having application in the clinical treatment of infection of DV and other members of flaviviridae. | 08-04-2011 |
20120196277 | DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESSMENT OF PROTEIN GLYCOSYLATION - Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy or disease states. | 08-02-2012 |
20130142827 | INDUCTION OF IMMUNE RESPONSE - Provided are methods and compositions that can be used to treat subjects having a viral infection by provoking an immune response using newly discovered antigens that are non-naturally occurring variations on viral glycoproteins. For example, provided are viral glycoproteins or a fragments thereof, or, DNA constructs encoding for such viral glycoproteins or fragments thereof, wherein the glycoprotein or fragment comprises a glycosylation sequon that includes a non-templated aspartic acid residue. | 06-06-2013 |
20130203092 | Lectin Assay for Assessing Glycoforms as an Early Marker in Disease - The present invention provides methods, compositions, apparatus, and kits for assessing glycoforms of proteins as a biomarker for disease. A purified recombinant form of lectin is used as a detector molecule to specifically label target sugars expressed in disease states. The high affinity of recombinant lectin allows for automation of assays that would be used in the diagnosis of diseases such as, but not limited to, cancer or liver disease. | 08-08-2013 |
20130280255 | IDENTIFICATION OF MODULATORS OF SERINE PROTEASE INHIBITOR KAZAL AND THEIR USE AS ANTI-CANCER AND ANTI-VIRAL AGENTS - This disclosure describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, the present disclosure provides, inter alia, an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this disclosure provides methods of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis). | 10-24-2013 |
20130303552 | NOVEL INHIBITORS OF SECRETION OF HEPATITIS B VIRUS ANTIGENS - Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient. | 11-14-2013 |
20140206666 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION - Pharmaceutical compositions of the invention comprise sulfamoylbenzamide derivative useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B virus (HBV) infection. | 07-24-2014 |
20140249154 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION - Pharmaceutical compositions of the invention are presented which comprise substituted aminothiazoles derivatives. The substituted aminothiazoles derivatives have a disease-modifying action in the treatment of diseases associated with unregulated cell growth. Such diseases include cancers such as hepatocellular carcinoma, and viral infections from a hepatitis virus. | 09-04-2014 |
20140308657 | SERINE PROTEASE INHIBITOR KAZAL ANTIBODIES - This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis). Also provided is an anti-SPIK antibody specific for an epitope comprising the first nine amino acids of intact SPIK. Further, a diagnostic kit is provided comprising at least one antibody specific for an epitope comprising the first nine amino acids of intact SPIK to diagnose patients exhibiting disease symptoms or at risk for developing a disease, wherein the disease is HBV infection, HCV infection, hepatitis, cancer or hepatic cancer. | 10-16-2014 |
20140335529 | METHOD OF TUMOR SCREENING - A method for tumor screening using urine of a mammal, the method includes obtaining a total urine nucleic acid (e.g., DNA) from a urine sample of a mammal, extracting a high molecular weight urine nucleic acid (above 1000 bp) by contacting the total urine nucleic acid with an adsorbent in the presence of a buffer which promotes binding of the high molecular weight urine nucleic acid to the adsorbent, replacing the buffer which promotes binding of the high molecular weight urine nucleic acid with a buffer which promotes binding of the low molecular weight urine nucleic acid to the adsorbent, extracting the low molecular weight urine nucleic acid by contacting with the adsorbent, eluting the low molecular weight urine nucleic acid, and assaying the low molecular weight urine nucleic acid for a presence or absence of a gene sequence specific to a certain type of tumor. | 11-13-2014 |
20150038515 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE - Pharmaceutical compositions of the invention comprise covalently closed circular DNA formation inhibitors having a disease-modifying action in the treatment of diseases associated with the formation of covalently closed circular DNA that include hepatitis B infection, and any disease involving formation of covalently closed circular DNA. | 02-05-2015 |
20150087659 | NOVEL INHIBITORS OF SECRETION OF HEPATITIS B VIRUS ANTIGENS - Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient. | 03-26-2015 |